Associated Papers
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities.
Li ES et al.
Npj Precision Oncology, 2025
40707668 (PubMed )
Supplement: 41698_2025_1053_MOESM2_ESM.xlsx › Suppl_Data_4
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
39876053 (PubMed )
Supplement: supplement_1.pdf
p53 mitigates the effects of oncogenic HRAS in urothelial cells via the repression of MCOLN1.
Jung J et al.
Iscience, 2021
34222845 (PubMed )
Supplement: mmc6.xlsx › Supplementary_Table_5
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
33802174 (PubMed )
Supplement: cancers-13-01215-s001.zip › Supplymentary_files › Supplymental_table.xlsx › TableS2
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
Nassar AH et al.
British Journal of Cancer, 2020
31857723 (PubMed )
Supplement: 41416_2019_686_MOESM1_ESM.xlsx › S2.2_Overall_SNV_small_indels
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
30593515 (PubMed )
Supplement: 10780432ccr183147-sup-209386_2_supp_5192871_ptz639.xlsx › S1.3_Raw_SNV_and_small_indels
Molecular characterization of medulloblastomas with extensive nodularity (MBEN).
Korshunov A et al.
Acta Neuropathologica, 2018
Select a paper to view details